Your session is about to expire
← Back to Search
Radiation Therapy + Durvalumab for Lung Cancer
Study Summary
This trial will test if adding a second cancer-fighting treatment to radiation therapy will improve outcomes for people with lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any serious ongoing illnesses that could affect my participation in the study.I am 20 years old or older.I have previously received treatments targeting my immune system.I have a history or current infection of TB, hepatitis B, hepatitis C, or HIV.You have participated in a previous study that involved durvalumab and/or tremelimumab, regardless of which treatment group you were in.I am not pregnant or breastfeeding and agree to use birth control during and up to 90 days after treatment.I have had cancer before, but it was either treated over 5 years ago, was a non-melanoma skin cancer, or was a carcinoma in situ, and I don't currently have any signs of cancer. I also haven't been diagnosed with a primary immunodeficiency.I haven't taken strong immune system suppressing drugs recently, except for small doses or specific exceptions.I am fully active or restricted in physically strenuous activity but can do light work.I haven't had autoimmune or inflammatory disorders in the past 2 years, except for allowed conditions.I don't have severe side effects from past cancer treatments, except for hair loss or skin changes.My lung cancer is at stage III and has been confirmed by a doctor.I have lasting side effects from past treatments that won't worsen with durvalumab.My advanced lung cancer worsened despite receiving specific chemotherapy and radiation.I have experienced severe side effects from previous immunotherapy.My lung cancer is a mix of small cell and non-small cell types.I am allergic to Durvalumab or its ingredients.My heart's electrical activity, measured by ECG, is within normal limits.I am eligible for or have completed a specific cancer treatment involving chemotherapy and radiation.I have had radiation therapy before, but not as part of my current lung cancer treatment.You are expected to live for more than 12 weeks.I have nerve damage that affects my daily activities.I am receiving chemoradiation therapy for advanced lung cancer.I have received an organ transplant from another person.I am not on cancer treatment but may be on hormone therapy for other reasons.I haven't had major surgery in the last 28 days that would interfere with treatment.
- Group 1: Hypofractionated radiation therapy (hfRT) with Durvalumab
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current quota of participants for this medical trial?
"Affirmative. Clinicaltrials.gov divulges that this medical trial, which was initially posted on July 15th 2021, is actively enrolling patients. 43 participants are needed across 1 clinical site."
Are there any common ailments which employ consolidative hypofractionated radiation therapy (hfRT) as a treatment?
"Consolidative hypofractionated radiation therapy (hfRT) is most commonly employed to treat stage III non-small cell lung cancer. It can also be used for cases such as metastatic ureter urothelial carcinoma and advanced directives when other treatments are not possible."
Are there still openings in this investigation for participants?
"This clinical trial is actively recruiting as attested to on the clinicaltrials.gov website, having first been made available for public access in July 2021 and with its most recent update occurring November 2022."
What other investigations have been completed concerning the effects of consolidative hypofractionated radiation therapy (hfRT)?
"At present, 333 clinical investigations are underway exploring the use of consolidative hypofractionated radiation therapy (hfRT), with 52 trials in Phase 3. Most studies based on this treatment can be found in Cordoba and Texas; however, there exist over 12 thousand other locations running hfRT trials."
Share this study with friends
Copy Link
Messenger